• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary Circulation >Effects of Ranolazine on Exercise Capacity, Right Ventricular Indices, and Hemodynamic Characteristics in Pulmonary Arterial Hypertension: A Pilot Study:
【24h】

Effects of Ranolazine on Exercise Capacity, Right Ventricular Indices, and Hemodynamic Characteristics in Pulmonary Arterial Hypertension: A Pilot Study:

机译：雷诺嗪对肺动脉高压运动能力，右心室指标和血流动力学特征的影响：一项初步研究：

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ranolazine, a late inward sodium current and fatty acid oxidation inhibitor, may improve right ventricular (RV) function in pulmonary arterial hypertension (PAH); however, the safety and efficacy of ranolazine in humans with PAH is unknown. Therefore, we sought to (1) determine whether ranolazine is safe and well tolerated in PAH and (2) explore ranolazine's effect on symptoms, exercise capacity, RV structure and function, and hemodynamic characteristics. We therefore conducted a 3-month, prospective, open-label pilot study involving patients with symptomatic PAH (n = 11) and echocardiographic evidence of RV dysfunction. We evaluated the safety and tolerability of ranolazine and compared symptoms, exercise capacity, exercise bicycle echocardiographic parameters, and invasive hemodynamic parameters between baseline and 3 months of ranolazine therapy using paired t tests. Of the 11 patients enrolled, one discontinued ranolazine therapy due to a drug-drug interaction after 3 days of therapy. All 10 of the remaining patients continued therapy for 3 months, and 8 (80%) of 10 completed all study tests. After 3 months, ranolazine administration was safe and associated with improvement in functional class (P = 0.0013), reduction in RV size (P = 0.015), improved RV function (improvement in RV strain during exercise at 3 months; P = 0.037), and a trend toward improved exercise time and exercise watts on bicycle echocardiography (P = 0.06 and 0.01, respectively). Ranolazine was not associated with improvement in invasive hemodynamic parameters. In conclusion, in a pilot study involving PAH, ranolazine therapy was safe and well tolerated, and it resulted in improvement in symptoms and echocardiographic parameters of RV structure and function but did not alter invasive hemodynamic parameters.
机译：雷诺嗪是一种晚期内向钠电流和脂肪酸氧化抑制剂，可改善肺动脉高压（PAH）中的右心室（RV）功能。然而，雷诺嗪对患有PAH的人的安全性和有效性尚不清楚。因此，我们试图（1）确定雷诺嗪在PAH中是否安全并且耐受性好;（2）探索雷诺嗪对症状，运动能力，RV结构和功能以及血液动力学特征的影响。因此，我们进行了为期3个月的前瞻性开放标签先导研究，涉及有症状的PAH（n = 11）和RV功能异常的超声心动图证据的患者。我们评估了雷诺嗪的安全性和耐受性，并使用配对t检验比较了雷诺嗪治疗的基线和3个月之间的症状，运动能力，运动自行车超声心动图参数和侵入性血液动力学参数。在入选的11名患者中，有1名在治疗3天后由于药物相互作用而终止了雷诺嗪治疗。其余所有10位患者继续治疗3个月，其中10位患者中有8位（80％）完成了所有研究测试。 3个月后，雷诺嗪的给药是安全的，并且与功能类别的改善（P = 0.0013），RV大小的减小（P = 0.015），RV功能的改善（3个月运动期间RV应变的改善; P = 0.037），以及自行车超声心动图上改善运动时间和运动瓦数的趋势（分别为P = 0.06和0.01）。雷诺嗪与侵入性血液动力学参数的改善无关。总之，在一项涉及PAH的试验研究中，雷诺嗪治疗是安全且耐受性良好的，可改善RV结构和功能的症状和超声心动图参数，但不会改变侵袭性血液动力学参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号